PositiveID Acquires MFSI to Bring Sample Prep, MDx Tech to Biodefense, Clinical Markets
May 19, 2011
PositiveID Acquires MFSI to Bring Sample Prep, MDx Tech to Biodefense, Clinical Markets
The deal, worth as much as $8.2 million, is expected to enable the medical-tech firm to expand into the biodefense and clinical diagnostics markets via MFSI's multiplexed molecular assays and automated, PCR-based sample-to-answer technology.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- PositiveID Developing Handheld Version of Cassette-based MDx Platform
May 2, 2013 / PCR Insider - MicroFluidic Systems Seeks Clinical Partners after Winning Key IP for MDx Cartridge Tech
March 29, 2012 / PCR Insider - Q&A: Johns Hopkins' David Dowdy on a Comparative Effectiveness Study of Cepheid's Xpert TB Test
May 30, 2013 / PCR Insider - Cepheid Highlights Strong Uptake of Xpert CT/NG as Q1 Revenues Rise 19 Percent
April 25, 2013 / PCR Insider - On Heels of FDA Approval, Cepheid's Xpert CT/NG Test Performs Well in Multi-Center Clinical Study
March 14, 2013 / PCR Insider